Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT - ON COMPLETION OF THE ISSUANCE OF THE THIRD TRANCHE SUPER SHORT-TERM COMMERCIAL PAPER FOR 2021（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

ON COMPLETION OF THE ISSUANCE OF

THE THIRD TRANCHE SUPER SHORT-TERM

COMMERCIAL PAPER FOR 2021

References are made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") dated 28 May 2020, 26 February 2021 and 25 May 2021 (the "Announcements"), in relation to, among others, the acceptance of the registration of the super short-term commercial paper of the Company by the Association. The registered amount of the super short-term commercial paper is RMB5 billion, which is effective for two years commencing from 19 May 2020, and issuable in tranches within the Effective Registration Period. The Company completed the issuance of the first and second tranche of super short-term commercial paper for 2021 in February 2021 and May 2021 in the aggregate principal amount of RMB1.5 billion and RMB1.5 billion, respectively. Unless otherwise specified, capitalized terms used herein shall have the same meaning as ascribed to them in the Announcements.

The Company has recently completed the issuance of the third tranche of super short-term commercial paper for 2021 (the "Current Tranche of Super Short-termCommercial Paper") within the above registered amount. The results of the issuance of Current Tranche of Super Short-term Commercial Paper are set out below:

Name of the Current Tranche of	The Third Tranche of Super Short-term Commercial Paper of
Super Short-term Commercial	Shanghai Fosun Pharmaceutical (Group) Co., Ltd. for 2021*
Paper	(上海復星醫藥（集團）股份有限公司2021年度第三期超短期融
	資券)
Short Name of the Current	21 Fosun Pharma	Code of the	012103477
Tranche of Super Short-term	SCP003* (21 復星	Current Tranche
Commercial Paper	醫藥SCP003)	of Super Short-
		term Commercial
		Paper
Aggregate principal amount	RMB1.2 billion	Term	210 days

1

Method of interest calculation	Repayment of the principal and interest in lump sum at fixed
	rate on maturity
Nominal value per unit	RMB100	Coupon rate	2.60%
Value date	18 September 2021	Payment date	16 April 2022
Leading underwriter	Bank of Shanghai Co., Ltd.
Joint leading underwriter	China Everbright Bank Company Limited

The relevant documents in relation to the Current Tranche of Super Short-term Commercial Paper have been published on the website of China Money at http://www.chinamoney.com.cn and the website of Shanghai Clearing House at http://www.shclearing.com.

This announcement does not constitute, or form part of, an offer or invitation, or solicitation or inducement of an offer, to subscribe for or purchase the Current Tranche of Super Short-term Commercial Paper or any of other securities of the Company, nor is this announcement circulated to invite offers for any securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, PRC

21 September 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

• for identification purposes only

2